Nuevolution in collaboration to develop drugs for epigenetic
21 Oct 2010
Copenhagen-based Nuevolution is collaborating with
EpiTherapeutics, ExpreS2ion Biotechnologies and the Biotech Research &
Innovation Centre (BRIC), University of Copenhagen, to identify and
develop novel small molecule drugs against epigenetic factors.
The DKK24M budget project is supported by the Danish High Technology
In the collaboration, Nuevolution will apply its proprietary and
powerful Chemetics technology to screen hundreds of millions small
molecules. All biology and disease skills and expertises needed for
the project to be successful are provided by EpiTherapeutics,
ExpreS2ion Biotechnologies and Professor Kristian Helin (BRIC).
“We are delighted with the establishment of this collaboration.
We believe that this consortium of skills represents the ideal
combination to efficiently identify and develop novel drug leads
toward epigenetic based disorders,” said Alex Gouliaev, CEO of
Nuevolution A/S. “It is with great pleasure we apply our Chemetics
technology within the exciting area of epigenetics and we are
looking forward to a successful collaboration”.